Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 Multi Center, Double Blind, Randomized, Placebo Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (pf 0495061), In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects

Next Previous
Trial Profile

Phase 3 Multi Center, Double Blind, Randomized, Placebo Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (pf 0495061), In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bococizumab (Primary)
  • Indications Cardiovascular disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms SPIRE-2
  • Sponsors Pfizer

Most Recent Events

  • 28 Aug 2023 Results (n=190) assessing the potential anti-inflammatory effects of PCSK9 inhibition using plasma proteomics from SPIRE-1/2 trials, presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology.
  • 18 Dec 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.
  • 08 Jan 2021 Results from CANTOS, JUPITER, SPIRE-1, SPIRE-2, and CIRT trials published in the European Heart Journal

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top